Jill M. Broadfoot
2022 - aTYR PHARMA
In 2022, Jill M. Broadfoot earned a total compensation of $913.5K as Chief Financial Officer at aTYR PHARMA, which was about the same as previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $132,610 |
|---|---|
| Option Awards | $274,076 |
| Salary | $414,395 |
| Stock Awards | $82,800 |
| Other | $9,612 |
| Total | $913,493 |
Broadfoot received $414.4K in salary, accounting for 45% of the total pay in 2022.
Broadfoot also received $132.6K in non-equity incentive plan, $274.1K in option awards, $82.8K in stock awards and $9.6K in other compensation.
Rankings
In 2022, Jill M. Broadfoot's compensation ranked 3,225th out of 5,736 executives tracked by ExecPay. In other words, Broadfoot earned more than 43.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,225 out of 5,736 | 44th |
Division Manufacturing | 1,814 out of 3,125 | 42nd |
Major group Chemicals And Allied Products | 864 out of 1,416 | 39th |
Industry group Drugs | 808 out of 1,317 | 39th |
Industry Biological Products, Except Diagnostic Substances | 193 out of 291 | 34th |
Source: SEC filing on April 5, 2024.
Broadfoot's colleagues
We found two more compensation records of executives who worked with Jill M. Broadfoot at aTYR PHARMA in 2022.
News
aTYR PHARMA CEO Sanjay Shukla's 2023 pay falls 46% to $1.3M
April 5, 2024
aTYR PHARMA CEO Sanjay Shukla's 2021 pay jumps 75% to $1.9M
March 22, 2022
aTYR PHARMA CEO Sanjay Shukla's 2020 pay jumps 63% to $1.1M
March 23, 2021
aTYR PHARMA CEO Sanjay Shukla's 2019 pay falls 52% to $664K
April 2, 2020
aTYR PHARMA CEO Sanjay Shukla's 2018 pay falls 36% to $1.4M
March 28, 2019